Ashland is a specialty chemicals company that makes functional ingredients and additives used in pharmaceuticals, personal care products, and industrial applications like paints and coatings. Ashland's products are not end products — they are ingredients that improve the performance of what its customers make. The two core product families are cellulosics (plant-derived polymers used as binders, thickeners, and controlled-release agents) and PVP (synthetic polymers used in pharma tablets and personal care formulations like hair sprays and toothpastes). Ashland operates through four segments: Life Sciences (pharma and food excipients), Personal Care (skin, hair, and oral care ingredients), Specialty Additives (rheology modifiers for paints and construction), and Intermediates (commodity chemical intermediates including BDO). In pharma, Ashland's excipients get specified into validated drug formulations, making them difficult and costly to swap out — creating recurring revenue and pricing stability. In Personal Care, margins depend on mix between commodity rheology modifiers and higher-margin biofunctional actives used in premium skin care. In Specialty Additives, margins are more volume-sensitive and face pressure from Chinese overcapacity in coatings chemicals. Ashland is executing a $90M cost savings program focused on SG&A cuts and manufacturing network consolidation. On the growth side, Ashland is targeting $100M in incremental sales from expanding high-value business lines like injectables and tablet coatings into new geographies, and another $100M from new technology platforms, most notably a bio-based chemistry called Transformed Vegetable Oil.